A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

Known as HKU5-CoV-2, the virus also appears capable of hooking onto other versions of ACE2 in multiple different mammals, ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

COVID-19 treatment called into question after major study In a nutshell A major study of 1.6 million seniors found that ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

As COVID-19 surged across the US starting in 2020, so too did the use of repurposed medications such as hydroxychloroquine and ivermectin to treat COVID-19 infections. Use of these medications ...

为解决疫苗和抗病毒药物预防新冠重症及死亡的时变效应不明确问题，香港大学研究人员开展相关研究。结果发现两者保护效力随时间变化，接种多剂疫苗有效但第四剂后有衰减，口服抗病毒药 5 天内使用效果好。对优化抗疫策略意义重大，推荐阅读。